Ellen Edgar, MD
Clinical Neurophysiology · Sunny Isl Bch, FLNPI 1326343625
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 444 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 35 manufacturers reported payments, led by AbbVie at 40.3% of the total. Reporting peaked in 2024 at $2,018 and has fallen 67.1% since, to $664 in 2025.
Across 444 payments — averaging $19.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$4K
- Pfizer$1K
- Novartis$556
- Amgen$456
- Biohaven Pharmaceutical Holding Company Ltd.$329
- Biohaven Pharmaceuticals, Inc.$326
- plus $3K from 29 others
What the payments were for
- Food & beverage$8,791100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 179 | $3,538 |
| Pfizer | 76 | $1,068 |
| Novartis | 34 | $556 |
| Amgen | 13 | $456 |
| Biohaven Pharmaceutical Holding Company Ltd. | 22 | $329 |
| Biohaven Pharmaceuticals, Inc. | 29 | $326 |
| Amneal Pharmaceuticals LLC | 10 | $243 |
| Lundbeck LLC | 8 | $223 |
| Biogen | 8 | $194 |
| Lilly USA, LLC | 8 | $175 |
| Neurocrine Biosciences, Inc. | 1 | $173 |
| Teva Pharmaceuticals USA, Inc. | 7 | $154 |
| Medtronic(2 entities) | 7 | $153 |
| Boston Scientific | 2 | $133 |
| AstraZeneca | 6 | $130 |
| SK Life Science, Inc. | 1 | $125 |
| Akcea Therapeutics, Inc. | 1 | $105 |
| UCB, Inc. | 5 | $99 |
| Jazz Pharmaceuticals Inc. | 5 | $86 |
| Abbott | 1 | $80 |
| Eisai Inc. | 3 | $70 |
| Sanofi | 2 | $52 |
| Merz Pharmaceuticals, LLC | 1 | $38 |
| Avanir Pharmaceuticals, Inc. | 2 | $34 |
| Bausch Health US, LLC | 2 | $33 |
| Promius Pharma LLC | 2 | $28 |
| Argenx US, Inc. | 1 | $26 |
| Merz North America, Inc. | 1 | $25 |
| Otsuka America Pharmaceutical, Inc. | 1 | $25 |
| Sunovion Pharmaceuticals Inc. | 1 | $23 |
| MDD US Operations, LLC | 1 | $22 |
| Corium, LLC | 1 | $20 |
| Harmony Biosciences LLC | 1 | $17 |
| Currax Pharmaceuticals LLC | 1 | $17 |
| Arbor Pharmaceuticals, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
Too few clinical neurophysiology providers in Floridato place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Nurtec OdtRimegepant Sulfate | 111 | $191,706 |
| BotoxOnabotulinumtoxina | 102 | $135,320 |
| UbrelvyUbrogepant | 83 | $117,043 |
| Dihydroergotamine Mesylate | 66 | $88,862 |
| Diclofenac Sodium | 97 | $73,124 |
| QuliptaAtogepant | 18 | $19,209 |
| Doxepin Hcl | 192 | $19,147 |
| Emgality PenGalcanezumab-Gnlm | 21 | $14,274 |
| MounjaroTirzepatide | 12 | $14,098 |
| NamzaricMemantine Hcl/Donepezil Hcl | 20 | $10,980 |
| Diclofenac Epolamine | 11 | $3,296 |
| Gabapentin | 331 | $2,892 |
| Donepezil Hcl | 337 | $2,585 |
| Oxcarbazepine | 28 | $2,415 |
| Memantine Hcl | 170 | $2,363 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieBotox, Ubrelvy, Qulipta, Namzaric | $3,538 | $282,552223 claims |
| PfizerNurtec Odt | $1,068 | $191,706111 claims |
| Lilly USA, LLCMounjaro | $175 | $14,09812 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few clinical neurophysiology providers in Floridaon file to place this against a meaningful peer group, so we don't.
Other clinical neurophysiology in Sunny Isl Bch
- Ernesto AlonsoLake City$211K
- Raam SambandamClermont$80K
- Noor YonoStuart$62K
- Rabih KashoutyStuart$34K
- Sheri BisbyWildwood$6K
- Isabella FerandoMiami$5K
- Joshua MendelsonFort Myers$3K
- Daniela RusoviciPort St John$3K
- Magdalena StepienOrlando$2K
- Suparna KrishnaiengarJacksonville$2K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.